748 related articles for article (PubMed ID: 23199901)
21. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
22. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
[TBL] [Abstract][Full Text] [Related]
23. Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes.
Papanikolaou V; Stefanou N; Dubos S; Papathanasiou I; Palianopoulou M; Valiakou V; Tsezou A
Cell Oncol (Dordr); 2015 Apr; 38(2):155-64. PubMed ID: 25539992
[TBL] [Abstract][Full Text] [Related]
24. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells.
Hong W; Chen L; Li J; Yao Z
Biochem Biophys Res Commun; 2010 May; 396(2):299-303. PubMed ID: 20406620
[TBL] [Abstract][Full Text] [Related]
26. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
27. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
[TBL] [Abstract][Full Text] [Related]
29. Lentivirus-mediated RNA interference targeting the ObR gene in human breast cancer MCF-7 cells in a nude mouse xenograft model.
Xue RQ; Gu JC; DU ST; Yu W; Wang Y; Zhang ZT; Bai ZG; Ma XM
Chin Med J (Engl); 2012 May; 125(9):1563-70. PubMed ID: 22800822
[TBL] [Abstract][Full Text] [Related]
30. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
[TBL] [Abstract][Full Text] [Related]
31. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.
Gonzalez-Villasana V; Gutiérrez-Puente Y; Tari AM
Oncol Rep; 2013 Sep; 30(3):1506-10. PubMed ID: 23783392
[TBL] [Abstract][Full Text] [Related]
32. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
33. Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells.
Garofalo C; Sisci D; Surmacz E
Clin Cancer Res; 2004 Oct; 10(19):6466-75. PubMed ID: 15475434
[TBL] [Abstract][Full Text] [Related]
34. Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting.
Fusco R; Galgani M; Procaccini C; Franco R; Pirozzi G; Fucci L; Laccetti P; Matarese G
Endocr Relat Cancer; 2010 Jun; 17(2):373-82. PubMed ID: 20410173
[TBL] [Abstract][Full Text] [Related]
35. Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression.
Applanat MP; Buteau-Lozano H; Herve MA; Corpet A
Adv Exp Med Biol; 2008; 617():437-44. PubMed ID: 18497067
[TBL] [Abstract][Full Text] [Related]
36. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
[TBL] [Abstract][Full Text] [Related]
37. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
Keeton EK; Brown M
Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
[TBL] [Abstract][Full Text] [Related]
38. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
Xiong H; Jin X; You C
Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
[TBL] [Abstract][Full Text] [Related]
39. Superactive human leptin antagonist (SHLA), triple Lan1 and quadruple Lan2 leptin mutein as a promising treatment for human folliculoma.
Fiedor E; Gregoraszczuk EL
Cancer Chemother Pharmacol; 2017 Oct; 80(4):815-827. PubMed ID: 28861689
[TBL] [Abstract][Full Text] [Related]
40. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
